New drugs, treatments, studies and clinical guidelines, summarised in plain language with a link to the original source.
New drugs
The FDA approves the first oral agent of its class for adults with migraine
The FDA approved lasmiditan (Reyvow), the first 5-HT1F receptor agonist for the acute treatment of migraine with or without aura in adults. Based on two phase 3 trials with 3,177 patients, the drug proved to be significantly superior to placebo in eliminating pain and the most bothersome symptom at 2 hours. For the patient, it represents a new oral therapeutic option, although it requires caution due to side effects such as dizziness and sedation, prohibiting driving or operating machinery for 8 hours after taking it.
Clinical practice guideline recommendations for the pharmacological treatment of migraine prevention in adults: Report of the AAN Guideline Subcommittee and the American Headache Society
This publication presents an update to the clinical practice guidelines based on a systematic review of studies until June 2024 in the United States. The multidisciplinary panel offers structured recommendations on when to start preventive treatment and how to choose the most suitable drug according to the patient profile. It includes specific guidelines for people with fibromyalgia, obesity, hypertension, older adults, and situations of pregnancy or breastfeeding. For the patient, this means more personalized care and clear criteria regarding efficacy, side effects, and when to stop the medication.
Migraine is added to the NHS England Pharmacy First program
NHS England announced the inclusion of low-frequency episodic migraine in its Pharmacy First program for autumn 2026. This initiative allows patients in England to receive assessment, advice, and prescription treatments directly at community pharmacies without a prior appointment with a GP. The change aims to reduce the treatment gap, as 29% of patients could not get a medical appointment when they needed it. For the patient, this means faster, closer, and more convenient access to professional care and necessary referrals.
Migraine prevention changes in 2026: it is no longer necessary to wait for it to become chronic
The new AAN and AHS guidelines for 2026 propose starting preventive treatment in earlier stages, without waiting for migraine to become chronic. It is recommended to act when the patient suffers 4 or more attack days per month or presents significant disability. The change allows access to traditional drugs (topiramate, propranolol) and new treatments against CGRP (atogepant, monoclonal antibodies) based on daily impact, improving quality of life and personalizing therapy according to each profile.
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomized, head-to-head, phase 3b trial
This phase 3b clinical trial compared atogepant against topiramate in 540 adults with migraine from 12 countries. The results showed that atogepant is better tolerated: only 12% discontinued treatment due to adverse effects compared to 30% with topiramate. Additionally, 64% of patients on atogepant reduced their migraine days by half, compared to 39% in the topiramate group. For the patient, this means a more effective oral preventive option with fewer side effects that make it easier to follow the treatment in the long term.
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a 156-week, open-label, multicenter phase 3 extension study
This interim analysis of a phase 3 study evaluated 595 patients with episodic and chronic migraine in the USA and other centers who used 60 mg daily of atogepant. After 52 weeks, a mean weight reduction of 2.16 kg was observed, and 29.5% of participants achieved clinically significant weight loss (≥5%). For the patient, this suggests that preventive treatment with atogepant is not only safe in the long term but could also favor weight reduction, especially in people with a high body mass index.
The European Commission has authorized the use of atogepant, a drug from the gepants class, for the acute treatment of migraine with or without aura in adults. Based on the 'Eclipse' study, the drug managed to eliminate pain in the majority of patients starting from 90 minutes and for up to 48 hours. This change is key for those who do not respond to other treatments, allowing the oral use of a drug that was previously only used as a preventive.
FDA grants De Novo authorization to Avulux lenses for migraine photophobia
The FDA authorized Avulux optical filter lenses to reduce the impact of light sensitivity in patients aged 12 and older with episodic migraine. This over-the-counter device blocks specific wavelengths (480 nm and 590 nm) without replacing acute or preventive treatments. The decision was based on randomized studies and real-world data, although the announcement did not detail efficacy or safety figures. For the patient, it represents a non-invasive and regulator-recognized option to manage photophobia as a complementary symptom.
The Canadian Drug Agency recommends reimbursement of UBRELVY® (ubrogepant) for the treatment of migraine attacks
The Canadian Drug Agency has issued a positive recommendation for the public reimbursement of UBRELVY (ubrogepant), an oral CGRP antagonist drug for adults with migraine with or without aura. The decision is based on phase III studies that demonstrated efficacy in the suppression and relief of pain and associated symptoms. This advancement in Canada expands specific therapeutic options for attacks, allowing for greater treatment personalization and improving access for patients with moderate to high intensity headaches.
The US FDA approves an over-the-counter Tylenol combination pill for pain relief
There is only a headline; the United States Food and Drug Administration (FDA) has authorized a new version of Tylenol that combines ingredients for pain treatment without the need for a medical prescription. Due to the absence of additional information in the source, there are no details available regarding the specific components of the formula, the clinical studies conducted, or the exact impact this drug will have for patients.
French migraine treatment: a breakthrough for 11 million patients
There is only a headline; the news announces a new breakthrough in a treatment of French origin intended to benefit 11 million people suffering from migraine. As the full text of the source is not available, it is not possible to detail the drug's mechanism, the type of clinical study conducted, or the specific results achieved, with current information being limited solely to the magnitude of the population potentially impacted by this therapeutic innovation in the French country.
This technical article from the University of Duisburg-Essen analyzes the management of medication-overuse headache (MOH) and prophylaxis in children. In adults with MOH, studies with erenumab (70/140 mg) and eptinezumab (100 mg) showed remissions of up to 69% and 40% respectively. For the pediatric population, a new study with fremanezumab is highlighted, which reduced episodic migraine days. These findings offer patients new effective therapeutic alternatives, such as monoclonal antibodies, compared to conventional treatments and the placebo effect.
Atogepant reduces migraine days by half in three out of ten refractory patients
This Spanish multicenter study, led by the Hospital de Bellvitge with 252 refractory patients, analyzed the effectiveness of the preventive drug atogepant in highly complex cases. The results show that 30% of patients who had not responded to previous treatments, including monoclonal antibodies, reduced their migraine days by half after three months. For the patient, this represents new therapeutic hope in difficult cases, achieving significant improvements in pain intensity and a lower need for rescue medication.
Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results from the RESOLUTION randomized trial
This phase 4 multinational clinical trial evaluated eptinezumab in 608 adults with chronic migraine and medication-overuse headache (MOH). After receiving education about MOH, patients treated with this monoclonal antibody showed sustained reductions in migraine frequency and days of acute medication use through week 24. The results indicate that the initial improvements in disease burden and quality of life are maintained after a second dose, resulting in many patients no longer meeting the diagnostic criteria for chronic migraine and MOH with a good safety profile.
New non-opioid analgesic, suzetrigine, reduces headache in single-center cohort
There is only a headline; it is announced that suzetrigine, a new non-opioid analgesic, has shown efficacy in reducing headache in a study conducted at a single research center. Since the full text is not available, details regarding the methodology, number of participants, or the exact magnitude of improvement are unknown. For the patient, this represents a possible future therapeutic alternative without the risks of opioids, although more data are required to confirm its actual clinical utility.
NICE approves atogepant for the acute treatment of migraine in the NHS of England
The British body NICE has approved the use of atogepant (Aquipta) as an acute treatment for adults with migraine in England. This gepant-type drug, which blocks CGRP, was already used as a preventive and can now be used during attacks. It is indicated for patients who have not responded to 2 triptans, paracetamol, or NSAIDs. For the patient, this represents a specific alternative for pain that reduces the risk of medication overuse headache and expands the available therapeutic options.
AEMPS starts the IPT for six drugs endorsed by the EMA in April
The Spanish Agency of Medicines (AEMPS) has started in Spain the preparation of the Therapeutic Positioning Report (IPT) for Aquipta (atogepant). After receiving European endorsement in April 2026, this drug seeks to expand its indication to include the acute treatment of migraine with or without aura in adults. For the patient, this represents a key administrative step toward the availability of a new therapeutic option to stop migraine attacks, pending its final price and reimbursement.
Anvisa approves migraine medication that dissolves in the mouth
There is only a headline; the National Health Surveillance Agency of Brazil has approved a new drug to treat migraine that is characterized by being a formulation that dissolves in the mouth. Due to the absence of additional information in the source, specific details about the commercial name of the product, its clinical efficacy, or when it will be available for patients in that country are not known.
Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis
This meta-analysis of seven clinical trials evaluated the efficacy of 75 mg of rimegepant in 6,734 adults with migraine. The results show that 19.8% of patients achieved pain freedom at two hours, compared to 10.7% with placebo, and 14.2% maintained that relief for 24 hours. The drug proved to be safe and well-tolerated. For the patient, this confirms that rimegepant is an effective and safe option, especially useful if conventional treatments do not work or are contraindicated.
Emgality, a medication for chronic migraine, is leaving the Brazilian market
The pharmaceutical company Libbs announced that the monoclonal antibody Emgality (galcanezumab) will stop being sold in Brazil starting June 2026 due to a portfolio update. This monthly injectable drug, approved in 2019, is a key ally for patients with chronic migraine and cluster headache who do not respond to other treatments. The withdrawal worries doctors and patients because of the difficulty in finding substitutes with the same efficacy and lower rate of side effects, directly impacting the quality of life of those who depend on this preventive.
Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine
This meta-analysis of 5 studies with 5,565 participants evaluated the use of rimegepant for migraine. The results show that the drug is effective in achieving pain relief and eliminating the most bothersome symptom at 2 hours after treatment (RR=1.34 and 1.38 respectively). For the patient, rimegepant offers a safe and well-tolerated option without significant adverse effects compared to placebo, although the study warns that it failed to demonstrate statistical efficacy in preventing pain recurrence between 2 and 48 hours later.
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: a phase 3, multicenter, 24-week, open-label study
This phase 3 study evaluated adding 60 mg of daily atogepant to 75 adult patients with chronic migraine who were already receiving onabotulinumtoxinA. The results showed a reduction of 7.2 migraine days per month after 24 weeks, and 61.9% of participants managed to reduce their attacks by half. Although there were side effects such as constipation and nausea, the treatment was safe and well-tolerated. For the patient, this validates combining two different preventive therapies to achieve superior disease control.
This analysis of the ADVANCE and ELEVATE clinical studies evaluates the drug atogepant (Aquipta®), an oral CGRP receptor antagonist for patients with episodic migraine in Germany. The results show a significant reduction of 4.1 migraine days per month compared to 2.5 with placebo, with a 50% response rate in 60% of users. For the patient, this represents an effective preventive option that acts within a few days, even when other conventional treatments have previously failed.
Long-term safety and efficacy of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study
This phase 3 study in Japan evaluated the safety and efficacy of rimegepant 75 mg over 52 weeks in 458 adults with migraine. The results showed an average reduction of 4.5 migraine days per month, and 55.4% of participants managed to reduce their attacks by half. The drug was well tolerated, with only 1.3% discontinuing due to adverse effects. For the patient, this confirms that rimegepant is a safe and effective long-term option to prevent attacks and improve quality of life.
FDA: EFFICACY supplement for RIZAFILM (RIZATRIPTAN benzoate)
There is only a headline; the FDA has registered an efficacy supplement for Rizafilm (rizatriptan benzoate) under code NDA205394. The source text does not provide additional details regarding the type of study conducted, the numerical results obtained, or the specific changes this implies for patient treatment. This is a technical update concerning the efficacy information for this drug commonly used to treat migraine attacks.
This press article summarizes the pharmaceutical innovations recently approved in the EU. Among the 38 new active ingredients, the oral CGRP receptor antagonists stand out for migraine patients: rimegepant (Vydura) and atogepant (Aquipta). While atogepant is used exclusively for the prophylaxis of episodic migraine, rimegepant offers the versatility of serving for both preventive treatment and acute attacks. This expands oral therapeutic options, allowing for more personalized and specific management of the disease.
Migraine management in children and adolescents: a systematic review of practice guidelines and recommendations
This systematic review analyzed 8 international clinical guidelines (such as AAN and NICE) published in the last decade regarding pediatric migraine. The results confirm the consensus on using paracetamol and ibuprofen as first-line treatment, and nasal sumatriptan or zolmitriptan as the second option. However, there is variability in doses and preventive treatments, with a lack of information identified regarding anti-CGRP drugs and neuromodulation. For the patient, this means that, while there are clear guidelines for rapid relief, prevention still needs to be better standardized.
The Spanish Society of Neurology launches its new Clinical Practice Manual on Headaches
The Spanish Society of Neurology (SEN) has published the fifth edition of its reference manual for healthcare professionals in Spain. This update incorporates the latest advances in monoclonal antibodies, gepants and biological therapies against migraine, which affects 14% of the population. For the patient, this ensures an approach based on the most recent scientific evidence, including new non-pharmacological strategies, digital tools and interventional techniques to improve diagnosis and quality of life in neurology and primary care consultations.
Gepants, ditans and monoclonal antibodies: the roadmap for Spanish Neurology to integrate the new therapeutic era in headaches
The Spanish Society of Neurology has published its fifth clinical guideline on headaches, which updates the treatment for more than five million patients in Spain. The document highlights the efficacy of monoclonal antibodies and the new gepants and ditans, which improve functional capacity and offset economic costs within three months. Despite the advances, the guide denounces access barriers in the public system. The patient will benefit from care that now integrates surgery, digital health, and exercise recommendations for the first time.
Fremanezumab in children and adolescents with episodic migraine
This randomized clinical trial evaluated the efficacy of fremanezumab in 234 participants aged 6 to 17 with episodic migraine. The results showed that the drug reduced the monthly average of migraine days by 2.5 compared to 1.4 in the placebo group, with 47.2% of patients reducing their attacks by half. For a young patient, this represents a new effective and safe preventive option, with injection site erythema being the most common adverse effect.
How much aerobic exercise is needed to reduce migraine? A dose-response meta-analysis on pain intensity and frequency
This meta-analysis of 15 studies with 253 patients analyzed the impact of aerobic exercise on migraine. The results show that exercise significantly reduces both pain intensity and frequency. For a moderate effect, at least 200 total minutes of activity are required, reaching the maximum benefit between 900 and 950 cumulative minutes during the program. For the patient, this translates into a preliminary recommendation to perform 3 weekly sessions of 30 minutes for about 10 or 11 weeks to optimize improvement.
2025 Guideline Update for the Acute Treatment of Migraine in Adults in the Emergency Department: Evidence Evaluation of Parenteral Pharmacotherapies from the American Headache Society
This systematic review and meta-analysis from the American Headache Society updates the recommendations for the treatment of migraine in the emergency department for adults after evaluating 26 new clinical trials. It concludes that treatment with IV prochlorperazine and greater occipital nerve blocks should be offered as a priority due to their high efficacy. Conversely, the use of IV hydromorphone is strongly discouraged and IV paracetamol is questioned. For the patient, this ensures more effective management of acute pain through validated injectable therapies, avoiding ineffective drugs.
Comparative efficacy and safety of preventive treatments for vestibular migraine: a systematic review and network meta-analysis
This network meta-analysis analyzed 5 clinical trials with 419 patients to compare preventive drugs against vertigo in vestibular migraine. The results show that all evaluated treatments significantly reduced monthly attacks. Propranolol stood out with the largest theoretical reduction (-7.04 attacks/month), followed by valproic acid and venlafaxine. However, galcanezumab presented the best balance between efficacy, quality of evidence, and tolerability with no dropouts. For the patient, this validates classic and new options to decrease the frequency of vertigo and improve their quality of life.
Neurology News Network: Notable FDA Approvals in 2025
The FDA expanded the indication of fremanezumab (Ajovy) to include the prevention of episodic migraine in pediatric patients aged 6 to 17 years with a minimum weight of 45 kg. Based on the phase 3 SPACE study with 237 children, the drug demonstrated superior efficacy to placebo over 12 weeks with a consistent safety profile. This milestone is fundamental for pediatric patients, as fremanezumab becomes the first anti-CGRP treatment approved for both adults and migraine prevention in children.
The relationship between lifestyle behaviors and tension-type headache and migraine: a systematic review and meta-analysis
This systematic review and meta-analysis of 7 studies with 32,197 participants analyzed the impact of modifiable factors on migraine and tension-type headache. The results showed no significant associations between alcohol consumption, body mass index, smoking, or physical activity and the risk of suffering from these disorders. For a patient, this suggests that, according to current limited evidence, these specific habits might not be direct causes of the disease, although more high-quality research is required to confirm these findings.
AbbVie to present Phase 3 ECLIPSE data demonstrating the superiority of atogepant (AQUIPTA®) over placebo in achieving pain freedom for the acute treatment of migraine at the 19th European Headache Congress
This Phase 3 clinical study (ECLIPSE) conducted with 1,223 adults in Europe, Asia, and the United Kingdom analyzed the drug atogepant for treating acute migraine attacks. The results show that 24.3% of patients achieved pain freedom two hours after treatment, compared to 13.1% in the placebo group, also meeting the goal of eliminating the most bothersome symptom. For the patient, this means that atogepant, already used as a preventive, could become a new effective option to stop migraine attacks at the moment they occur.
Addressing unmet needs in migraine: effectiveness of fremanezumab in real-world conditions in PEARL study participants with at least three previous preventive treatment failures
This post-hoc analysis of the European PEARL study evaluated the effectiveness of fremanezumab in 398 patients with episodic and chronic migraine who had previously failed three or more preventive treatments. The results showed that 53.8% of participants achieved a reduction in their monthly migraine days of at least 50% during the first six months. For the patient, this confirms that the drug is a safe and effective option in real clinical practice, even when other traditional preventive treatments have not worked correctly.
Greater occipital nerve block for migraine treatment: an overview, systematic review, and meta-analysis
This meta-analysis and review of 16 clinical trials evaluated the efficacy of the greater occipital nerve block (GONB) in 930 patients. The results show that the use of local anesthetic reduces pain intensity in acute attacks after 30 minutes. In chronic migraine, weekly injections reduced pain and monthly migraine days by 4.46 days after one month. For the patient, this confirms that it is a safe and useful procedure for rapid relief, although evidence on long-term benefits or steroid use is still limited.
Early and sustained change in headache day frequency after eptinezumab treatment in adults with migraine in whom 2 to 4 prior preventive treatments failed: a post hoc analysis of the DELIVER randomized trial
This analysis of the DELIVER trial evaluated the use of intravenous eptinezumab in adults with migraine who did not respond to 2-4 prior preventives. The results show that 23% of patients reduced their headache days to fewer than 4 per month in the first 12 weeks, a figure that rose to 47% by the end of the study (weeks 61-72). Furthermore, 9% achieved zero days of pain after the last dose. For the patient, this represents a sustained improvement in pain intensity and disease burden, even in difficult-to-treat cases.
Marketing of Reyvow for migraine treatment suspended, according to the FDA
The pharmaceutical company Eli Lilly has decided to suspend the manufacturing of Reyvow (lasmiditan), a drug for the acute treatment of migraine with or without aura in adults approved in 2019. According to the FDA, this decision is due to commercial and competitive reasons, ruling out safety or efficacy issues. For the patient, this means that this 5-HT 1F receptor agonist will stop being available soon. Due to its sedative side effects and the restriction of not driving for eight hours after taking it, it is recommended to seek therapeutic alternatives with your specialist.
Enough of migraine, here are the new oral drugs that eliminate attacks in 7 out of 10 patients
This article details the impact of gepants (atogepant and rimegepant) in Italy, oral drugs that block the CGRP peptide. Studies published in Lancet show that 7 out of 10 patients control their attacks, achieving relief within two hours and efficacy for up to 48 hours. They are indicated for adults with episodic or chronic migraine (minimum 8 days per month) who did not respond to previous therapies. For the patient, this represents a prevention and acute treatment option funded by the public system that restores daily normality.
Migraine: a new innovative treatment with highly controlled access
There is only a headline; the news published by the outlet Le Soir reports on the existence of a new innovative treatment for migraine that stands out for having very restricted or controlled access for patients. Due to the absence of text in the source, it is not possible to detail the type of drug, the mechanism of action, the country of application, or the specific criteria required to receive this new therapeutic option.
Acupuncture recommendations for migraine in headache treatment guidelines: a systematic review
This systematic review evaluated 25 global guidelines on the use of acupuncture for migraine. The results show that, although 40% recommend its use, the methodological quality is low and 77.8% lack details about the procedure. Only 4% of the guidelines offer high-quality recommendations. For the patient, this means that, although acupuncture is a recognized option, the lack of clear standards in current medical guidelines makes precise and uniform clinical application difficult.
Rimegepant for the acute treatment of migraine in adults not suitable for triptans: A phase 4 randomized, double-blind, placebo-controlled trial
This phase 4 clinical trial analyzed the efficacy of a 75 mg dose of rimegepant in 585 adults who cannot use triptans due to lack of efficacy, intolerance, or contraindications. The results showed that 55.9% of patients achieved pain relief at 2 hours, compared to 32.7% in the placebo group, in addition to improving functionality and reducing the need for rescue medication. For the patient, this confirms that gepants are a safe and effective alternative when conventional treatments fail or are contraindicated.
Phase 4, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications
This multinational phase 4 trial evaluated rimegepant (75 mg) in 652 adults with episodic migraine who previously did not respond to 2 to 4 traditional preventive drugs. The results showed that rimegepant reduced monthly migraine days significantly more than placebo (-2.1 vs. -0.5 days) and increased the probability of reducing severe attacks by half by 20%. For the patient, this represents an effective and safe option to prevent attacks when common oral treatments have failed.
FDA approves botulinum toxin A for severe chronic migraine
There is only a headline; the U.S. Food and Drug Administration (FDA) has announced the approval of botulinum toxin type A specifically for the treatment of severe chronic migraine. Due to the absence of text in the source, data on clinical trials, attack reduction figures, or the specific population studied are not available. For the patient, this represents the confirmation of a regulated therapeutic option for severe cases of this condition.
New migraine drugs approved in the EU: "they are very well tolerated"
The EU has approved 'gepants' (atogepant and rimegepant), a new class of oral drugs for adults that block the CGRP receptor. Rimegepant stands out for being the first authorized for both prevention and acute treatment. Unlike triptans, they do not constrict blood vessels, being safe for patients with cardiovascular risk. Although a meta-analysis suggests an acute efficacy somewhat lower than triptans, their pill format and short duration offer a versatile and well-tolerated alternative to injectable antibodies.
FDA: efficacy supplement for Vyepti (eptinezumab-jjmr)
There is only a headline; the FDA has registered an efficacy supplement related to the drug Vyepti (eptinezumab-jjmr) under identifier BLA761119. Due to the brevity of the report, details regarding the type of study, the population analyzed, or specific result figures are not available. For the patient, this represents an administrative update in progress that does not yet allow for the determination of specific changes or additional benefits in their current migraine treatment.
Closing the gap between evidence and clinical practice for migraines: a systematic review (2019-2024)
This systematic review analyzed 169 randomized clinical trials on migraine published between 2019 and 2024 worldwide to evaluate their clinical usefulness. The results show that, although 50.9% exceed the average usefulness and 98.8% are patient-centered, less than 2% are considered of high usefulness. Serious deficiencies persist in data transparency (1.8%) and economic evaluations (0.6%). For the patient, this means that current research does not yet fully translate into practical, equitable, and accessible improvements for their daily treatment.
Migraine-related disability according to headache frequency subclassifications: a systematic review and meta-analysis
This systematic review and meta-analysis of 32 studies evaluated disability in patients with low-frequency episodic migraine (0-7 days per month), high-frequency (8-14 days), and chronic (15+ days). Results show that disability increases linearly with attack frequency. It highlights that between 42% and 44% of people with high-frequency migraine already present severe disability. For the patient, this validates that the need for intensive treatment should be based on both frequency and functional impact.
International Headache Society evidence-based clinical practice guideline on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine
This International Headache Society guideline reviewed 15 clinical studies to evaluate non-invasive neuromodulation devices. Weak recommendations were issued for the acute use of SAVI Dual, Cefaly, Relivion, and Nerivio, and for the preventive use of gammaCore Sapphire, Cefaly, and Nerivio. For the patient, these devices represent a safe, well-tolerated alternative without drug interactions compared to traditional drugs, although the quality of current evidence varies from very low to moderate due to small sample sizes.
Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results from the SUNRISE randomized, double-blind, placebo-controlled trial
This phase 3 clinical trial analyzed the efficacy of eptinezumab in 978 adults with chronic migraine, primarily from Asia. The study demonstrated that the 100 mg and 300 mg doses reduced monthly migraine days by 7.2 and 7.5 respectively, compared to 4.8 days in the placebo group. For the patient, this represents an effective preventive option that offers relief from the first day of treatment and a significant reduction in attacks with a well-tolerated safety profile.
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter, randomized, double-blind, placebo-controlled PRECLUDE trial
This phase 3 clinical trial conducted at multiple centers evaluated the efficacy of onabotulinumtoxinA in 775 adult patients with episodic migraine. The results showed that, although there was a reduction in monthly migraine days, there was no statistically significant difference between the 155 U or 195 U doses compared to placebo. Secondary objectives in reducing acute medication were also not met. For the patient, this confirms that Botox is not more effective than placebo in cases of episodic migraine, unlike its proven use in chronic migraine.
Adjunctive occipital nerve block for the emergency treatment of acute migraine: A randomized controlled trial
This randomized trial in adults evaluated the efficacy of adding a greater occipital nerve block (methylprednisolone and lidocaine) to standard intravenous triple therapy in the emergency department. Results showed that 95.2% of patients with the block achieved a 50% pain reduction within two hours, compared to 47.6% in the control group. At 30 days, patients reported fewer migraine days and more pain-free days. For the patient, this procedure offers rapid and lasting relief in cases of severe or refractory attacks.